Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling

Wilding, B; Scharn, D; Bose, D; Baum, A; Santoro, V; Chetta, P; Schnitzer, R; Botesteanu, DA; Reiser, C; Kornigg, S; Knesl, P; Hormann, A; Koferle, A; Corcokovic, M; Lieb, S; Scholz, G; Bruchhaus, J; Spina, M; Balla, J; Peric-Simov, B; Zimmer, J; Mitzner, S; Fett, TN; Beran, A; Lamarre, L; Gerstberger, T; Gerlach, D; Bauer, M; Bergner, A; Schlattl, A; Bader, G; Treu, M; Engelhardt, H; Zahn, S; Fuchs, JE; Zuber, J; Ettmayer, P; Pearson, M; Petronczki, M; Kraut, N; McConnell, DB; Solca, F; Neumuller, RA

Wilding, B; Solca, F; Neumuller, RA (通讯作者)，Boehringer Ingelheim RCV, Vienna, Austria.

NATURE CANCER, 2022; 3 (7): 821

Abstract

Neumuller and colleagues identify and characterize potent HER2 exon 20 insertion-selective inhibitors with efficacy, which preserve wild-type epiderma......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索